These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 8686349

  • 21. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U.
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [Abstract] [Full Text] [Related]

  • 22. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV, Cohen RD.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1179-86. PubMed ID: 17944732
    [Abstract] [Full Text] [Related]

  • 23. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R.
    Clin Gastroenterol Hepatol; 2003 Jan 01; 1(1):36-43. PubMed ID: 15017515
    [Abstract] [Full Text] [Related]

  • 24. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Jan 01; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 25. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
    d'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, Bardazzi G, Milla M, Ferrero S, Biagini M, Quaranta S, Amorosi A.
    Am J Gastroenterol; 1997 Jul 01; 92(7):1143-7. PubMed ID: 9219787
    [Abstract] [Full Text] [Related]

  • 26. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE.
    Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1094-102. PubMed ID: 18363894
    [Abstract] [Full Text] [Related]

  • 27. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A, Behrens C, Bias P.
    Aliment Pharmacol Ther; 2004 Dec 01; 20(11-12):1353-63. PubMed ID: 15606398
    [Abstract] [Full Text] [Related]

  • 28. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V, International Salofalk Foam Study Group.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1237-49. PubMed ID: 17944738
    [Abstract] [Full Text] [Related]

  • 29. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P.
    Aliment Pharmacol Ther; 1989 Apr 01; 3(2):183-91. PubMed ID: 2577483
    [Abstract] [Full Text] [Related]

  • 30. Ulcerative colitis therapy: importance of delivery mechanisms.
    Rochester J, Abreu MT.
    Rev Gastroenterol Disord; 2005 Apr 01; 5(4):215-22. PubMed ID: 16369217
    [Abstract] [Full Text] [Related]

  • 31. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG.
    Lancet; 1992 May 23; 339(8804):1279-81. PubMed ID: 1349676
    [Abstract] [Full Text] [Related]

  • 32. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR, Zakko S, Gordon GL, Murthy U, Sedghi S, Pruitt R, Merchant K, Bortey E, Forbes WP.
    Aliment Pharmacol Ther; 2012 Jul 23; 36(2):126-34. PubMed ID: 22617015
    [Abstract] [Full Text] [Related]

  • 33. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H, Munakata A, Yoshida Y.
    J Gastroenterol; 1995 Nov 23; 30 Suppl 8():115-7. PubMed ID: 8563870
    [Abstract] [Full Text] [Related]

  • 34. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM, Greenberg GR.
    Am J Gastroenterol; 1988 Jan 23; 83(1):15-9. PubMed ID: 2892391
    [Abstract] [Full Text] [Related]

  • 35. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN.
    J Gastroenterol; 1995 Nov 23; 30 Suppl 8():112-4. PubMed ID: 8563869
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK, Irvine EJ.
    Am J Gastroenterol; 2000 Jul 23; 95(7):1628-36. PubMed ID: 10925961
    [Abstract] [Full Text] [Related]

  • 38. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.
    Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, Chiaramonte M, Caprilli R.
    Dig Liver Dis; 2005 Feb 23; 37(2):92-6. PubMed ID: 15733520
    [Abstract] [Full Text] [Related]

  • 39. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schütz E, Otto P, Lorenz-Mayer H, Ewe K, Judmaier G.
    Aliment Pharmacol Ther; 1998 Aug 23; 12(8):707-15. PubMed ID: 9726382
    [Abstract] [Full Text] [Related]

  • 40. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N, Weir DG, Kelleher D.
    Ir J Med Sci; 1999 Aug 23; 168(4):228-32. PubMed ID: 10624358
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.